Quarterly report pursuant to Section 13 or 15(d)

Segment Disclosures

v3.23.1
Segment Disclosures
 3 Months Ended
Mar. 31, 2023
Segment Reporting [Abstract]  
Segment Disclosures Segment Disclosures
 
The Company has two reportable segments: EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. The reportable segments are each managed separately because they serve distinct markets.

The Company evaluates performance and allocates resources based on segment gross profit margin. The Company does not consider net assets as a segment measure and, accordingly, assets are not allocated.
 
Segment reporting information is as follows:
  EksoHealth EksoWorks Total
Three months ended March 31, 2023      
Revenue $ 3,997  $ 125  $ 4,122 
Cost of revenue 1,951  171  2,122 
Gross profit $ 2,046  $ (46) $ 2,000 
Three months ended March 31, 2022      
Revenue $ 1,881  $ 686  $ 2,567 
Cost of revenue 1,015  343  1,358 
Gross profit $ 866  $ 343  $ 1,209 

The Company operates in the following regions: (1) Americas, (2) Europe, the Middle East, and Africa (EMEA), and (3) Asia Pacific (APAC). Individual countries with revenue greater than 10% of total revenue for the three months ended March 31, 2023 and 2022 are disclosed separately from the regional totals. Geographic information for revenue based on location of customers is as follows:

  Three Months Ended March 31,
  2023 2022
Americas
   United States $ 2,958 $ 1,343
   Other 4  55 
Americas 2,962  1,398 
EMEA
   Germany 244  124 
   Other 512  440 
EMEA 756  564 
APAC
Japan —  280 
   Other 404  325 
APAC 404  605 
 Total Revenue $ 4,122  $ 2,567